In the last 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) shares. These analysts typically work for major Wall Street banks and are tasked with understanding a company's performance and predicting how its stock will trade over the next year.
| up | A little up | Indifference | A little bear | Bear | |
|---|---|---|---|---|---|
| General standards | 5 | 2 | 0 | 0 | 0 |
| In the last 30 days | 1 | 1 | 0 | 0 | 0 |
| A million ago | 1 | 1 | 0 | 0 | 0 |
| 2 million years ago | 0 | 0 | 0 | 0 | 0 |
| 3 months ago | 3 | 0 | 0 | 0 | 0 |
These seven analysts have an average price target of $13.29, compared to ATAI Life Sciences' current price of $1.3447, indicating a bearish trend.
A summary of how these seven analysts rated ATAI Life Sciences over the past three months. The higher the rating, the more positive analysts are about the stock, and the lower the rating, the more negative analysts are about the stock.
This average price is 48.88% lower than the previous average of $26.00.
Stay up-to-date with the ATAI Life Sciences Analyst Rankings.
If you want to follow penny stock news and performance you can follow it here.
Analysts are specialists in banking and the financial system and usually report on specific stocks or sectors. These people review the company's financial statements, participate in conference calls and meetings, and talk with key people to determine what the analyst ratings for the stock should be. Typically, analysts review each stock once a quarter.
Some analysts publish forecasts on metrics such as growth, earnings and revenue estimates to provide additional guidance in their estimates. When using analyst ratings, remember that stock and industry analysts are also human and provide their opinions only to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings in Benzinga Pro along with analyst top scores.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
